Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 43 studies | 43% ± 21% | |
smooth muscle cell | 27 studies | 33% ± 13% | |
pericyte | 22 studies | 32% ± 16% | |
connective tissue cell | 14 studies | 34% ± 9% | |
myofibroblast cell | 13 studies | 38% ± 16% | |
plasmacytoid dendritic cell | 8 studies | 22% ± 6% | |
astrocyte | 7 studies | 29% ± 11% | |
mesothelial cell | 7 studies | 29% ± 17% | |
adventitial cell | 5 studies | 47% ± 19% | |
endothelial cell | 4 studies | 19% ± 2% | |
precursor B cell | 4 studies | 43% ± 12% | |
immature B cell | 3 studies | 33% ± 11% |
Insufficient scRNA-seq data for expression of AEBP1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 38531.27 | 457 / 459 | 94% | 556.75 | 1052 / 1118 |
skin | 87% | 17297.95 | 1565 / 1809 | 99% | 971.12 | 465 / 472 |
prostate | 98% | 32163.91 | 240 / 245 | 86% | 191.87 | 434 / 502 |
lung | 100% | 37740.38 | 577 / 578 | 83% | 235.44 | 957 / 1155 |
uterus | 100% | 60927.00 | 170 / 170 | 65% | 191.19 | 300 / 459 |
ovary | 100% | 55721.56 | 180 / 180 | 65% | 201.96 | 278 / 430 |
bladder | 100% | 34920.71 | 21 / 21 | 58% | 174.55 | 294 / 504 |
thymus | 96% | 21187.42 | 628 / 653 | 61% | 125.64 | 372 / 605 |
intestine | 93% | 20623.80 | 899 / 966 | 62% | 170.70 | 325 / 527 |
kidney | 81% | 18261.64 | 72 / 89 | 64% | 240.44 | 574 / 901 |
esophagus | 78% | 18759.40 | 1134 / 1445 | 66% | 172.77 | 120 / 183 |
stomach | 59% | 13297.38 | 213 / 359 | 66% | 186.73 | 189 / 286 |
adrenal gland | 78% | 10499.97 | 201 / 258 | 34% | 64.18 | 78 / 230 |
blood vessel | 100% | 186538.43 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 558.32 | 80 / 80 |
adipose | 100% | 41778.06 | 1201 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 5% | 559.62 | 18 / 328 | 91% | 552.13 | 162 / 178 |
spleen | 88% | 13222.41 | 211 / 241 | 0% | 0 | 0 / 0 |
brain | 13% | 1540.91 | 353 / 2642 | 52% | 174.25 | 364 / 705 |
heart | 61% | 15697.93 | 525 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 56% | 136.69 | 25 / 45 |
lymph node | 0% | 0 | 0 / 0 | 52% | 79.11 | 15 / 29 |
liver | 8% | 1003.38 | 18 / 226 | 26% | 49.63 | 104 / 406 |
muscle | 10% | 1154.21 | 81 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 29.31 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_1904026 | Biological process | regulation of collagen fibril organization |
GO_0006518 | Biological process | peptide metabolic process |
GO_0016485 | Biological process | protein processing |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0005615 | Cellular component | extracellular space |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005201 | Molecular function | extracellular matrix structural constituent |
GO_0005516 | Molecular function | calmodulin binding |
GO_0004181 | Molecular function | metallocarboxypeptidase activity |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0005518 | Molecular function | collagen binding |
GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | AEBP1 |
Protein name | AE binding protein 1 Adipocyte enhancer-binding protein 1 (AE-binding protein 1) (Aortic carboxypeptidase-like protein) |
Synonyms | ACLP |
Description | FUNCTION: [Isoform 1]: As a positive regulator of collagen fibrillogenesis, it is probably involved in the organization and remodeling of the extracellular matrix. .; FUNCTION: [Isoform 2]: May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor. . |
Accessions | ENST00000450684.2 [Q8IUX7-2] H7C391 ENST00000449162.1 ENST00000223357.8 [Q8IUX7-1] H7C4B5 H7C0W8 H7C3D7 ENST00000431035.1 Q8IUX7 ENST00000434445.1 ENST00000455443.5 C9JLQ8 ENST00000413907.1 ENST00000453052.1 H7C1J5 |